Procter & Gamble Forecast, price target & analysts
Procter & Gamble Target price 2025 - Analyst rating & recommendation
Procter & Gamble Classifications & Recommendation:
Procter & Gamble Price Target
| Target Price | $179.01 |
| Price | $150.58 |
| Potential | 18.88% |
| Number of Estimates | 29 |
| 29 Analysts have issued a price target Procter & Gamble 2026 . The average Procter & Gamble target price is $179.01. This is 18.88% higher than the current stock price. The highest price target is $195.30 29.70% , the lowest is $145.65 3.27% . | |
| A rating was issued by 35 analysts: 23 Analysts recommend Procter & Gamble to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Procter & Gamble stock has an average upside potential 2026 of 18.88% . Most analysts recommend the Procter & Gamble stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2032
28 Analysts have issued a sales forecast Procter & Gamble 2026 . The average Procter & Gamble sales estimate is $89.6b . This is 6.30% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $92.1b 9.24% , the lowest is $83.7b 0.71% .
This results in the following potential growth metrics:
Revenue Estimates
| 2025 | $84.3b | 0.29% |
|---|---|---|
| 2026 | $89.6b | 6.30% |
| 2027 | $92.3b | 3.07% |
| 2028 | $95.7b | 3.65% |
| 2029 | $98.4b | 2.85% |
| 2030 | $102b | 3.86% |
| 2031 | $107b | 4.50% |
| 2032 | $111b | 3.70% |
24 Analysts have issued an Procter & Gamble EBITDA forecast 2026. The average Procter & Gamble EBITDA estimate is $25.1b . This is 6.10% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $26.5b 11.99% , the lowest is $23.4b 1.09% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $23.6b | 1.87% |
|---|---|---|
| 2026 | $25.1b | 6.11% |
| 2027 | $26.3b | 4.82% |
| 2028 | $27.6b | 4.92% |
| 2029 | $28.1b | 1.79% |
| 2030 | $29.1b | 3.81% |
| 2031 | $29.9b | 2.55% |
| 2032 | $31.0b | 3.70% |
EBITDA Margin
| 2025 | 28.02% | 1.58% |
|---|---|---|
| 2026 | 27.97% | 0.19% |
| 2027 | 28.45% | 1.72% |
| 2028 | 28.79% | 1.20% |
| 2029 | 28.50% | 1.01% |
| 2030 | 28.48% | 0.07% |
| 2031 | 27.95% | 1.86% |
| 2032 | 27.95% | 0.00% |
27 Procter & Gamble Analysts have issued a net profit forecast 2026. The average Procter & Gamble net profit estimate is $16.9b . This is 7.67% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $17.5b 11.31% , the lowest is $15.9b 1.10% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2025 | $15.7b | 7.45% |
|---|---|---|
| 2026 | $16.9b | 7.67% |
| 2027 | $17.9b | 6.02% |
| 2028 | $19.0b | 6.03% |
| 2029 | $19.4b | 2.03% |
| 2030 | $20.4b | 5.24% |
| 2031 | $21.7b | 6.52% |
| 2032 | $22.9b | 5.67% |
Net Margin
| 2025 | 18.61% | 7.14% |
|---|---|---|
| 2026 | 18.84% | 1.26% |
| 2027 | 19.39% | 2.92% |
| 2028 | 19.83% | 2.27% |
| 2029 | 19.67% | 0.81% |
| 2030 | 19.93% | 1.32% |
| 2031 | 20.32% | 1.96% |
| 2032 | 20.71% | 1.92% |
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
27 Analysts have issued a Procter & Gamble forecast for earnings per share. The average Procter & Gamble EPS is $7.20 . This is 12.32% higher than earnings per share in the financial year 2025. The highest EPS forecast is $7.44 16.07% , the lowest is $6.76 5.46% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2025 | $6.38 | 8.14% |
|---|---|---|
| 2026 | $7.20 | 12.85% |
| 2027 | $7.64 | 6.11% |
| 2028 | $8.10 | 6.02% |
| 2029 | $8.26 | 1.98% |
| 2030 | $8.69 | 5.21% |
| 2031 | $9.26 | 6.56% |
| 2032 | $9.79 | 5.72% |
P/E ratio
| Current | 23.49 | 20.85% |
|---|---|---|
| 2026 | 20.91 | 10.99% |
| 2027 | 19.72 | 5.69% |
| 2028 | 18.60 | 5.68% |
| 2029 | 18.23 | 1.99% |
| 2030 | 17.32 | 4.99% |
| 2031 | 16.26 | 6.12% |
| 2032 | 15.39 | 5.35% |
Based on analysts' sales estimates for 2026, the Procter & Gamble stock is valued at an EV/Sales of 4.21 and an P/S ratio of 3.93 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.48 | 10.93% |
|---|---|---|
| 2026 | 4.21 | 5.98% |
| 2027 | 4.09 | 2.97% |
| 2028 | 3.94 | 3.52% |
| 2029 | 3.83 | 2.77% |
| 2030 | 3.69 | 3.72% |
| 2031 | 3.53 | 4.30% |
| 2032 | 3.41 | 3.57% |
P/S ratio
| Current | 4.18 | 11.78% |
|---|---|---|
| 2026 | 3.93 | 5.93% |
| 2027 | 3.82 | 2.97% |
| 2028 | 3.68 | 3.52% |
| 2029 | 3.58 | 2.77% |
| 2030 | 3.45 | 3.71% |
| 2031 | 3.30 | 4.31% |
| 2032 | 3.18 | 3.57% |
Procter & Gamble...
Current Procter & Gamble Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 01 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Sep 25 2025 |
| BNP Paribas |
Outperform
➜
Outperform
|
Unchanged | Aug 15 2025 |
| Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 31 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Jul 30 2025 |
| JP Morgan |
Overweight
➜
Neutral
|
Downgrade | Jul 25 2025 |
| UBS |
Buy
➜
Buy
|
Unchanged | Jul 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Oct 01 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Sep 25 2025 |
|
Unchanged
BNP Paribas:
Outperform
➜
Outperform
|
Aug 15 2025 |
|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Jul 31 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Jul 30 2025 |
|
Downgrade
JP Morgan:
Overweight
➜
Neutral
|
Jul 25 2025 |
|
Unchanged
UBS:
Buy
➜
Buy
|
Jul 17 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
